222 related articles for article (PubMed ID: 8118750)
1. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy.
Hassager C; Jensen LT; Pødenphant J; Thomsen K; Christiansen C
Calcif Tissue Int; 1994 Jan; 54(1):30-3. PubMed ID: 8118750
[TBL] [Abstract][Full Text] [Related]
2. The carboxy-terminal propeptide of type I procollagen in serum as a marker of bone formation: the effect of nandrolone decanoate and female sex hormones.
Hassager C; Jensen LT; Johansen JS; Riis BJ; Melkko J; Pødenphant J; Risteli L; Christiansen C; Risteli J
Metabolism; 1991 Feb; 40(2):205-8. PubMed ID: 1988778
[TBL] [Abstract][Full Text] [Related]
3. Effect of the menopause and hormone replacement therapy on the carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen.
Hassager C; Risteli J; Risteli L; Christiansen C
Osteoporos Int; 1994 Nov; 4(6):349-52. PubMed ID: 7696831
[TBL] [Abstract][Full Text] [Related]
4. Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate?
Johansen JS; Hassager C; Pødenphant J; Riis BJ; Hartwell D; Thomsen K; Christiansen C
Bone Miner; 1989 Apr; 6(1):77-86. PubMed ID: 2665884
[TBL] [Abstract][Full Text] [Related]
5. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study.
Gennari C; AgnusDei D; Gonnelli S; Nardi P
Maturitas; 1989 Sep; 11(3):187-97. PubMed ID: 2687645
[TBL] [Abstract][Full Text] [Related]
6. Bone resorption in healthy and osteoporotic postmenopausal women: comparison markers for serum carboxy-terminal telopeptide of type I collagen and urinary pyridinium cross-links.
Välimäki MJ; Tähtelä R; Jones JD; Peterson JM; Riggs BL
Eur J Endocrinol; 1994 Sep; 131(3):258-62. PubMed ID: 7921210
[TBL] [Abstract][Full Text] [Related]
7. The androgenic anabolic steroid nandrolone decanoate prevents osteopenia and inhibits bone turnover in ovariectomized cynomolgus monkeys.
Jerome CP; Power RA; Obasanjo IO; Register TC; Guidry M; Carlson CS; Weaver DS
Bone; 1997 Apr; 20(4):355-64. PubMed ID: 9108356
[TBL] [Abstract][Full Text] [Related]
8. [Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis].
Gennari C; Agnusdei D; Gonnelli S
Minerva Endocrinol; 1989; 14(1):69-74. PubMed ID: 2659955
[TBL] [Abstract][Full Text] [Related]
9. Double-blind placebo--controlled trial of nandrolone decanoate in postmenopausal osteoporosis.
Chhaparwal M; Saraf ML
Indian J Med Sci; 1998 Jun; 52(6):236-8. PubMed ID: 9849033
[No Abstract] [Full Text] [Related]
10. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
Katagiri M; Fukunaga M; Ohtawa T; Harada T
World J Surg; 1996 Sep; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
[TBL] [Abstract][Full Text] [Related]
11. Serum concentration of the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful indicator of decline and recovery of bone mineral density in lumbar spine: analysis in Japanese postmenopausal women with or without hormone replacement.
Yasumizu T; Hoshi K; Iijima S; Asaka A
Endocr J; 1998 Feb; 45(1):45-51. PubMed ID: 9625445
[TBL] [Abstract][Full Text] [Related]
12. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy.
Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Pons F; Martínez de Osaba MJ; Echevarría M; Ballesta AM; Muñoz-Gómez J
Bone; 1999 Sep; 25(3):349-53. PubMed ID: 10495139
[TBL] [Abstract][Full Text] [Related]
13. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment.
Gertz BJ; Clemens JD; Holland SD; Yuan W; Greenspan S
Calcif Tissue Int; 1998 Aug; 63(2):102-6. PubMed ID: 9685512
[TBL] [Abstract][Full Text] [Related]
14. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
[TBL] [Abstract][Full Text] [Related]
15. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
[TBL] [Abstract][Full Text] [Related]
16. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
Okabe R; Inaba M; Nakatsuka K; Miki T; Naka H; Moriguchi A; Nishizawa Y
J Bone Miner Metab; 2004; 22(2):127-31. PubMed ID: 14999523
[TBL] [Abstract][Full Text] [Related]
17. Nocturnal rise in markers of bone resorption is not abolished by bedtime calcium or calcitonin.
Sairanen S; Tähtelä R; Laitinen K; Karonen SL; Välimäki MJ
Calcif Tissue Int; 1994 Nov; 55(5):349-52. PubMed ID: 7866915
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH.
Persani L; Preziati D; Matthews CH; Sartorio A; Chatterjee VK; Beck-Peccoz P
Clin Endocrinol (Oxf); 1997 Aug; 47(2):207-14. PubMed ID: 9302396
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of serum pyridinoline cross-linked carboxy-terminal telopeptides of type I collagen and osteocalcin in the study of the bone resorption rate in oophorectomized rats.
Calero JA; De la Piedra C; Díaz Curiel M
Miner Electrolyte Metab; 1998; 24(5):303-6. PubMed ID: 9705565
[TBL] [Abstract][Full Text] [Related]
20. Collagen synthesis in postmenopausal women during therapy with anabolic steroid or female sex hormones.
Hassager C; Jensen LT; Pødenphant J; Riis BJ; Christiansen C
Metabolism; 1990 Nov; 39(11):1167-9. PubMed ID: 2233278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
